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ABSTRACT 
 
Despite their clinical significance, characterization of balanced chromosomal abnormalities (BCAs) has 
largely been restricted to cytogenetic resolution. We explored the landscape of BCAs at nucleotide 
resolution in 273 subjects with a spectrum of congenital anomalies. Whole-genome sequencing revised 
93% of karyotypes and revealed complexity that was cryptic to karyotyping in 21% of BCAs, 
highlighting the limitations of conventional cytogenetic approaches. At least 33.9% of BCAs resulted in 
gene disruption that likely contributed to the developmental phenotype, 5.2% were associated with 
pathogenic genomic imbalances, and 7.3% disrupted topologically associated domains (TADs) 
encompassing known syndromic loci. Remarkably, 8 subjects harbored BCA breakpoints that localized 
to a single TAD encompassing MEF2C, a known driver of the 5q14.3 microdeletion syndrome, resulting 
in altered MEF2C expression by genomic rewiring. This study proposes that sequence-level resolution 
dramatically improves prediction of clinical outcomes for balanced rearrangements and provides insight 
into novel pathogenic mechanisms such as altered regulation due to changes in chromosome topology. 
 
 
Keywords: Cytogenetics, structural variation, balanced chromosomal abnormality, congenital anomaly, 
intellectual disability, autism, translocation, inversion, chromothripsis, topologically associated domain 
(TAD), MEF2C 
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Balanced chromosomal abnormalities (BCA) are a class of structural variation that involve 1 
rearrangement of chromosome structure and result in a change in the orientation or localization of a 2 
genomic segment without a large concomitant gain or loss of DNA. This class of variation includes 3 
inversions, translocations, excisions/insertions, and more complex rearrangements consisting of 4 
combinations of such events. Cytogenetic studies of unselected newborns and control adult males 5 
estimate a prevalence of 0.2-0.5% for BCAs in the general population1-3. By contrast, an approximate 6 
five-fold increase in the prevalence of BCAs detected by karyotyping has been reported among subjects 7 
with neurodevelopmental disorders, particularly intellectual disability (1.5%)4 and autism spectrum 8 
disorder (ASD; 1.3%)5. These data suggest that BCAs represent highly penetrant mutations in a 9 
meaningful fraction of subjects with associated congenital anomalies or neurodevelopmental disorders. 10 
 11 
Delineating the breakpoints of BCAs and the genomic regions that they disrupt has long been a fertile 12 
area of novel gene discovery in human genetic research and has greatly contributed to the annotation of 13 
the morbid map of the human genome6-8. Despite their significance in human disease, the clinical 14 
detection of this unique class of chromosomal rearrangements still relies upon conventional cytogenetic 15 
methods such as karyotyping that are limited to microscopic resolution (~3-10 Mb, depending on the 16 
chromosome banding pattern and specimen type)9. The absence of gross genomic imbalances renders 17 
BCAs invisible to higher resolution techniques that currently serve as first-tier diagnostic screens for 18 
many developmental anomalies of unknown etiology: chromosomal microarray (CMA), which can 19 
detect microscopic and sub-microscopic copy-number variants (CNVs), or whole-exome sequencing 20 
(WES), which surveys single nucleotide variants within coding regions. Without access to precise 21 
breakpoint localization, clinical interpretation of de novo BCAs has been limited to estimates of an 22 
untoward outcome from population cytogenetic studies based solely on the presence of a rearrangement 23 
(6.1% of de novo reciprocal translocations, 9.4% for de novo inversions)10. We have recently shown that 24 
innovations in genomic technologies can efficiently reveal BCA breakpoints at nucleotide resolution 25 
with a cost and timeframe comparable to clinical CMA or karyotyping; however, only a limited number 26 
of BCAs has been evaluated to date11,12,7,13-16. 27 
 28 
In this study, we explored several fundamental but previously intractable questions regarding de novo 29 
BCAs associated with human developmental anomalies, such as the origins of their formation, the 30 
genomic properties of the sequences that they disrupt, and the mechanisms by which BCAs act as 31 
dominant pathogenic mutations. We evaluated 273 subjects ascertained based upon the presence of a 32 
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BCA discovered by karyotyping in a cytogenetics laboratory in a proband that presented with a 33 
developmental anomaly.  We defined the genomic sequences that were altered by the breakpoints and 34 
created a framework in which we interpreted their significance based on convergent genomic datasets. 35 
This included CNV and WES data in tens of thousands of individuals, as well as prediction of long-36 
range regulatory effects from recent studies that have established high-resolution maps of chromosomal 37 
compartmentalization in the nucleus17,18. Our findings indicate that formation of BCAs involves a 38 
variety of mechanisms and sequence characteristics, that the end-result often reflects substantial 39 
complexity invisible to cytogenetic assessment, that BCAs directly disrupt genes likely to contribute to 40 
early developmental abnormalities in at least one-third of subjects, and that BCAs can cause long-range 41 
regulatory changes due to alterations to the chromosome structure. These results highlight the myriad 42 
genomic features of BCAs that have been largely unexplored in conventional cytogenetic research and 43 
demonstrate mechanisms by which they contribute to abnormalities in human development. 44 
45 
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RESULTS 46 
Sequencing BCAs reveals cryptic complexity  47 
In this study 273 subjects were sequenced originating from five primary referral sites that collectively 48 
represented an international consortium of over 100 clinical investigators. Subjects harbored a BCA that 49 
was detected by karyotyping and presented with varied developmental anomalies. Most of the 273 50 
subjects were surveyed using large-insert whole-genome sequencing (liWGS or ‘jumping libraries’; 51 
83%), with the remainder of subjects being analyzed by standard short-insert WGS or targeted 52 
breakpoint sequencing (see Online Methods; Supplementary Table 1). Subjects were preferentially 53 
selected with confirmed de novo BCAs based on cytogenetic studies at the referring site or with 54 
rearrangements that segregated with a phenotypic anomaly within a family (72.5% of subjects); 55 
however, inheritance information was unavailable for one or both parents in the remaining 27.5% of 56 
subjects. Notably, subjects harboring BCAs that were inherited from an unaffected parent were excluded 57 
from this study. Of interest, 62.6% of subjects received clinical CMA screening prior to enrollment to 58 
confirm the absence of a pathogenic CNV (Table 1). Subjects presented with a spectrum of clinical 59 
features: congenital anomalies ranged from organ-specific disorders to multisystem abnormalities, as 60 
well as neurodevelopmental conditions such as intellectual disability or autism spectrum disorder (ASD; 61 
Table 1). While no specific phenotypes were prioritized for inclusion (see Supplementary Fig. 1), 62 
neurological defects were the most common feature in the cohort (80.2% of subjects when using 63 
digitalized phenotypes from Human Phenome Ontology [HPO]19; Table 1; Supplementary Table 2). 64 
 65 
Breakpoints were identified in 248 of the 273 cases (90.8%); all subsequent analyses were restricted to 66 
these 248 subjects. This success rate was consistent with expectations, as simulation of one million 67 
random breakpoints in the genome and comparison against all uniquely alignable 10 bp – 100 bp kmers 68 
suggests that 7.6% of simulated breakpoints were localized within N-masked regions or genomic 69 
segments that cannot be confidently mapped by short-read sequencing (Supplementary Fig. 2). 70 
Sequencing identified 876 breakpoints genome-wide (Fig. 1a) and revised the breakpoint localization by 71 
at least one sub-band in 93% of subjects when compared to the karyotype interpretation (breakpoint 72 
positions provided in Supplementary Table 3). Across all rearrangements, 26% (n=65) of BCAs were 73 
found to be complex (i.e., involved three or more breakpoints), including 5.3% (n=13) that were 74 
consistent with the phenomena of chromothripsis or chromoplexy that we and others have previously 75 
defined in cancer genomes and the human germline (complex reorganization of the chromosomes 76 
involving extensive shattering and random ligation of fragments from one or more chromosomes)20-24. 77 
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The most complex BCA involved 57 breakpoints (Supplementary Fig. 3). When analyses were 78 
restricted to the 230 subjects for which the karyotype suggested a simple chromosomal exchange, 48 79 
(21%) were determined to be rearrangements with complexity that was cryptic to the karyotype, 80 
emphasizing the insights that are gained from nucleotide resolution. Across all BCAs, 80.7% resolved to 81 
less than ten kilobases of total genomic imbalance, although several cases harbored large cryptic 82 
imbalances (mostly deletions) of varied impact (Fig. 1b, Supplementary Table 4). Importantly, 9.3% 83 
of BCAs displayed an overall genomic imbalance greater than 1 Mb and only 12.2% had imbalances of 84 
>100 kb in this study, representing a significantly lower fraction than previous cytogenetic estimates25. 85 
The overall genomic imbalance associated with a BCA was larger among cases without CMA pre-86 
screening, and 15.5%/18.8% of these subjects harbored imbalances greater than 1 Mb/100 kb, 87 
respectively (Fig. 1b, Supplementary Table 4). The total genomic imbalance generally increased with 88 
the number of breakpoints, though there were chromothripsis and chromoplexy events that were 89 
essentially balanced (e.g., subject NIJ19 involved 13 junctions across five chromosomes that resolved to 90 
a final genomic imbalance of only 631 bases). 91 
 92 
BCA formation is mediated by multiple molecular mechanisms 93 
Extensive mechanistic studies have been performed on breakpoints of large CNV datasets; however, the 94 
limited scale and resolution of BCA studies have precluded similar analyses for balanced 95 
rearrangements. Using precise junction sequences from 662 breakpoints, we found that nearly half 96 
displayed signatures of blunt-end ligation (45%), presumably driven by non-homologous end joining 97 
(NHEJ) (Fig. 1c). A substantial fraction (29%) involved microhomology of 2-15 bp at the breakpoint 98 
junction (median: 3-bp microhomology), indicating that template-switching coupled to DNA-replication 99 
mechanisms such as microhomology-mediated break-induced replication (MMBIR) contribute to a 100 
substantial fraction of BCAs26. A comparable fraction (25%) of junctions harbored micro-insertions of 101 
several basepairs (1 to 375 inserted bases, median: 6-bp), consistent with NHEJ or fork stalling and 102 
template switching (FoSTeS) mechanisms (Fig. 1c). Finally, only nine junctions (1%) contained long 103 
stretches of homologous sequences (>100 bp) that would be consistent with homology-mediated repair. 104 
It is important, however, to note that this is almost certainly an underestimate given the limitations of 105 
short-read sequencing to capture rearrangements localized within highly homologous sequences such as 106 
segmental duplications or microsatellites. BCA breakpoint signatures from this study were also 107 
compared to 8,943 deletion breakpoints identified in 1,092 samples from the 1000 Genomes Project27. 108 
BCA breakpoints were enriched for blunt-end signatures while depleted for microhomology and large 109 
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homology sequences compared to deletion breakpoints (Supplementary Fig. 4), suggesting that they 110 
arose from distinct mechanisms.  111 
 112 
Comparison of the observed breakpoints to 100,000 independent sets of simulated breakpoints that 113 
retained the properties of the observed dataset (see Online Methods) established nominal enrichment 114 
for repeat elements (P=0.015) and fragile sites (P=0.043), while no significant enrichment for the other 115 
genomic features tested (recombination hotspots, DNAse-I hypersensitive sites, or transcription factor 116 
binding sites; Supplementary Fig. 5). Incorporating Hi-C interaction data to explore the association 117 
between nuclear organization of the chromosomes and BCA formation revealed that pairs of loci 118 
comprising a BCA breakpoint did not stem from regions with significantly higher contact patterns in the 119 
nucleus18; however, pairs of BCA breakpoint loci displayed genome-wide interaction patterns that were 120 
marginally more correlated than random pairings (P=0.046; see Supplementary Methods and 121 
Supplementary Fig. 6). These results suggest that DNA fragments involved in BCA formation are more 122 
likely to be co-localized in the same or neighboring subcompartments prior to chromosomal reassembly, 123 
though at the sample sizes available they did not necessarily harbor increased direct interactions.  124 
 125 
BCA breakpoints associated with congenital anomalies are enriched for functionally relevant loci 126 
While protein-coding sequences represent less than 2% of the human genome, the total genic space in 127 
which a structural variation can disrupt a transcript is considerable as the cumulative coverage of 128 
transcribed regions is over 60% based on recent annotations28. Consistent with this expectation, 67% 129 
(589/876) of all breakpoints in this study disrupted a gene, and at least one gene was truncated in most 130 
BCAs (75%, 186/248), which did not deviate from random expectations (observed n=408 RefSeq genes, 131 
expected n=392±20, P=0.220; Supplementary Fig. 7). While BCA breakpoints were not enriched for 132 
gene disruptions beyond expectations, the properties of the disrupted genes deviated significantly from 133 
randomly simulated breakpoints for several key features, as described below, suggesting that the 134 
pathogenic impact of BCAs in this cohort ascertained based upon the presence of a developmental 135 
abnormality is not a consequence of their likelihood to disrupt genes but rather a reflection of the 136 
gene(s) that they alter (the list of all disrupted genes at breakpoints is provided in Supplementary Table 137 
5). 138 
 139 
We observed a significant enrichment for disruption of genes highly intolerant to truncating mutations, 140 
as defined by two independent groups (P=0.027 and P=0.001 for Residual Variation Intolerance Score 141 
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[RVIS] and probability of loss-of-function [LoF] intolerance [pLI] scores, respectively; Fig. 2a)29,30. 142 
Embryonically expressed genes (P=0.001)31 and genes previously associated with autosomal dominant 143 
disorders (P=0.002) were also more likely to be disrupted than expected by chance, whereas no 144 
enrichment was observed for genes associated with autosomal recessive disorders (P=0.294; Fig. 2a)32. 145 
The strongest enrichment at breakpoints was detected for genes previously associated with 146 
developmental disorders (≥2 de novo LoF mutations [dnLoF]) as amalgamated from multiple 147 
independent datasets (P=2x10-5; Supplementary Table 6). Significant enrichment was also observed at 148 
breakpoints for FMRP-target genes and chromatin remodeling genes33,34, replicating the enrichment 149 
observed for genes with dnLoF in subjects with neurodevelopmental disorders (Fig. 2b)35-37,7,38,31. No 150 
enrichments were observed for CHD8 target genes39,40. When further incorporating expression data of 151 
the developing brain from BrainSpan41, truncated genes showed higher expression patterns during early 152 
developmental stages than randomly simulated datasets (Supplementary Fig. 8). These results appeared 153 
to be specific to early developmental anomalies; there was no significant enrichment of genes associated 154 
with schizophrenia42,43, or gene-sets associated with complex disorders that were considered as negative 155 
controls such as type-II diabetes, cancer, or height. Given the distribution of clinical phenotypes in the 156 
cohort, we hypothesized that enrichment signals were driven by the predominance of neurological 157 
abnormalities among the subjects. We therefore performed analyses that segregated subjects with or 158 
without nervous system related conditions using HPO-reported phenotypes, and replicated most 159 
associations for the subset of cases with neurological conditions while enrichments were not significant 160 
for the smaller subset of subjects without reported nervous system abnormalities (Supplementary Fig. 161 
9).   162 
 163 
BCAs predominantly contribute to developmental anomalies by direct gene truncation 164 
We next asked the fundamental question: “How often does a BCA represent a likely pathogenic 165 
mutation that contributes to the subject’s abnormal developmental phenotype?” We sought to interpret 166 
the clinical significance of each BCA with reference to the phenotype reported in the proband and the 167 
genomic region(s) altered by the rearrangement. We built our interpretation using categories comparable 168 
to those established by ClinVar and the Deciphering Developmental Disorders consortium (DDD)44; 169 
however, we restricted interpretation of variants of potential clinical relevance to Pathogenic or Likely 170 
Pathogenic, as detailed below and in Supplementary Table 7. All other variants were interpreted as 171 
Variant of Unknown Significance (VUS), as we lacked sufficient clinical and functional data to interpret 172 
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variants as Benign or Likely Benign. The overall summary of the predicted impact for each mapped BCA 173 
is provided in Supplementary Table 8. 174 
 175 
Pathogenic: We compared loci disrupted by BCAs to genes that had been robustly associated with 176 
dominant developmental disorders (≥3 reported cases with dnLoF in OMIM, DDD, and amalgamated 177 
large-scale sequencing studies in neurodevelopmental disorders; see Supplementary Methods and 178 
Supplementary Table 6). In total, 66 subjects (26.6%) harbored Pathogenic BCAs that disrupted these 179 
previously defined developmental loci either through direct gene disruption or genomic imbalance (Fig. 180 
2c; Table 2; Supplementary Table 9). In the majority of these subjects (53/66), the rearrangement 181 
truncated a high confidence syndromic locus. These included known drivers of recurrent microdeletion 182 
syndromes (e.g., SATB2, MBD5, EHMT1, NFIA, ZBTB20)45-49, loci associated with imprinted disorders 183 
(SNURF-SNRPN), and genes well-established as highly penetrant loci in developmental disorders (e.g., 184 
CHD7, CHD8, CDKL5, CUL3, DYRK1A, GRIN2B), as well as more recently implicated genes such as 185 
AHDC1, CTNND2 and WAC (Fig. 2c; Table 2; Supplementary Table 9). Several genes were disrupted 186 
in two or more subjects in this cohort, further confirming their significant role in developmental 187 
anomalies: AUTS2, KDM6A, MBD5, MYO6, MYT1L, PHF21A, PHIP, SNURF-SNRPN, SOX5 and 188 
ZBTB20. Importantly, ten subjects harbored BCAs that disrupted genes associated with dominant 189 
disorders for which the expected phenotype such as cardiovascular defects, childhood or late-onset 190 
hearing loss, neurodegenerative disorder, were not observed in the proband (Supplementary Table 9); 191 
in those subjects the rearrangements were likely incidental findings, but could alternatively represent 192 
pleiotropy in which disruption of the same locus can manifest in multiple distinct phenotypes. In the 193 
remaining 13 subjects with Pathogenic BCAs (13/66), genomic imbalances at the breakpoints either 194 
overlapped with known microdeletion/microduplication syndromes, or encompassed a gene associated 195 
with a dominant developmental disorder (e.g., 12p12.1-p11.22 deletion encompassing SOX5; Table 2; 196 
Fig. 2c). 197 
 198 
Likely Pathogenic: Each specific rearrangement effectively represents a private event, or an N-of-1, 199 
which is a major challenge for interpretation in genomic studies. To interpret variants as Likely 200 
Pathogenic when the BCA did not disrupt established developmental loci, we relied on convergent 201 
genomic evidence from large-scale datasets. The premise was that candidate genes associated with 202 
congenital anomalies or early developmental defects would show evidence of reduced reproductive 203 
fitness and intolerance to haploinsufficiency. Thirty-one subjects harbored BCAs that were considered 204 
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as Likely Pathogenic via direct loci disruption (Table 2; Supplementary Tables 8, 10). In 25 subjects, 205 
the rearrangement directly disrupted a gene highly intolerant to dnLoF, and in which dnLoF mutations 206 
had been previously reported in isolated cases (1 or 2 subjects, with an additional subject now 207 
represented by the BCA in our study; e.g. CACNA2D3, ROBO2, NFIB), some of which had strong 208 
biological support for involvement in developmental anomalies (EP400, STXBP5, NRXN3). Among 209 
those proposed candidate genes, several were disrupted in multiple subjects from the cohort (NPAS3(x4), 210 
PTPRZ1(x3), SYNCRIP(x2); Table 2, Supplementary Tables 10-11). Two subjects had BCAs likely 211 
associated with genomic disorders: one BCA involving a 2p21-p13.3 duplication encompassing NRXN1, 212 
one BCA disrupting the imprinted 11p15 region likely associated with Silver-Russel syndrome 213 
(MIM#180860). In the remaining four subjects with Likely Pathogenic BCAs, the rearrangement 214 
truncated genes that were established to be associated with developmental disorders yet in which only 215 
activating or missense mutations had been previously reported (e.g., CACNA1C and GNB1)50,51, 216 
proposing a dosage sensitive model for these loci, comparable to recurrent genomic disorders. Based on 217 
these results, we interpreted that 12.5% (31/248) of subjects harbored a BCA that was likely 218 
contributing to the phenotype through the involvement of potentially novel candidate genes or disease 219 
mechanisms. 220 
 221 
Collectively, these data suggest that 39.1% (97/248) of subjects have a phenotype that can be at least 222 
partially explained by haploinsufficiency or dosage alteration of an individual gene or locus (Fig. 2c; 223 
Supplementary Tables 8-10). Importantly, the overall diagnostic yield was significantly higher in 224 
subsets of the group, such as among those subjects who harbored confirmed de novo or co-segregating 225 
BCAs compared to subjects for whom inheritance was unknown (Fig. 2d), or among subjects who had 226 
not been screened clinically by CMA prior to enrollment (Fig. 2e). Despite these substantial yields, the 227 
marked increase in the frequency of BCAs associated with birth defects compared to the general 228 
population still suggests that alternative mutational mechanisms other than gene disruption may account 229 
for the developmental defects in a fraction of subjects for which the BCAs were interpreted as VUS.  230 
We explored such potential mechanisms in this unique dataset.  231 
 232 
Positional effects via disruption of long-range regulatory interactions 233 
Clusters of BCA breakpoints within intergenic regions may suggest disruption of strong regulatory 234 
elements that contribute to disease manifestation via positional effects. Alternatively, this could reflect 235 
recurrent rearrangements due to fragile sites and/or recombination hotspots. To isolate genomic regions 236 
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in which an unusual number of BCA breakpoints were localized, we partitioned the genome into 1 Mb 237 
bins using a sliding window of 100 kb. Only one genomic segment, consisting of several contiguous 238 
genomic bins, achieved genome-wide significance (P=8×10-9; Fig. 3a). This segment localized to 239 
cytogenetic band 5q14.3 and involved breakpoints from a remarkable eight independent BCAs. Of these 240 
eight BCAs, one directly disrupted MEF2C at 5q14.3 while the other seven BCAs mapped to intergenic 241 
regions proximal and distal to MEF2C. Importantly, among the seven BCAs with intergenic disruption 242 
of 5q14.3, none included a breakpoint disrupting a locus of known significance elsewhere in the 243 
genome, suggesting that an alternative mechanism to direct gene disruption was operating in the 5q14.3 244 
region. 245 
 246 
All BCA breakpoints from the 5q14.3 cluster overlapped with the previously described 5q14.3 247 
microdeletion syndrome for which nearly 100 subjects have been reported, with MEF2C as the proposed 248 
genetic driver of the syndromic phenotypes observed (Fig. 3b)52-58. However, deletions have been 249 
reported in cases located in proximity to MEF2C but not encompassing this gene (Fig. 3b), and the 250 
presence of seven BCAs distal to MEF2C in this study both challenge the hypothesis that direct 251 
disruption of MEF2C is a necessary and sufficient cause of the syndrome. When combining three 252 
previously described subjects with reported BCAs distal to MEF2C with the eight subjects from our 253 
cohort, a total of 11 subjects harbor balanced rearrangement breakpoints localized to the same 1 Mb 254 
region within 5q14.3 (Fig. 3b)52,57,15. Only one BCA directly truncated MEF2C, while all 10 remaining 255 
BCAs were predicted to disrupt a topologically associated domain (TAD) containing MEF2C (Fig. 3b). 256 
TADs are structured chromatin domains of increased interactions that typically define a local regulatory 257 
unit bridging regulatory elements together with their target genes59. Their disruption by genomic 258 
rearrangements can lead to impaired gene regulation and therefore disease pathogenesis60,61. 259 
Correspondingly, in the four subjects that harbored BCA breakpoints up to 860 kb distal to MEF2C for 260 
which RNA from lymphoblastoid cell lines (LCLs) was available, analysis of MEF2C expression 261 
revealed a significant reduction in all four subjects compared to 16 age-matched controls divided equally 262 
by sex (Fig. 3d). These analyses provide compelling evidence that alteration of the TAD architecture in 263 
this genomic disorder region can disrupt normal MEF2C expression. When integrated with existing data, 264 
the converging clinical features suggest multiple distinct mutational mechanisms resulting in 265 
phenocopies of the 5q14.3 microdeletion syndrome: (1) direct disruption of MEF2C via dnLoF 266 
mutations, (2) deletions including MEF2C, and (3) long-range positional effects from deletions and 267 
BCAs not impacting MEF2C via alteration to the physical orientation of the TAD structure (Fig. 3c). 268 
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 269 
Beyond 5q14.3, we also identified three other loci (2q33.1, 6q14.3 and 14q12) suggestive of an 270 
accumulation of BCA breakpoints, although these loci did not reach genome-wide significance (P=1x10-271 
4). Each segment contained BCA breakpoints from four independent subjects and overlapped with 272 
known microdeletion syndromes (Fig. 3a). At 2q33.1, one BCA disrupted SATB2, associated with Glass 273 
syndrome and recognized as the established driver of the 2q33.1 microdeletion syndrome47,7, while the 274 
remaining three rearrangements were predicted to impact long-range interactions between SATB2 and its 275 
regulatory elements, similar to the effect observed with MEF2C at 5q14.3 (Supplementary Fig. 10). In 276 
the 14q12 cluster, all BCA breakpoints were distal to FOXG1, which has been reported in atypical Rett 277 
syndrome62-65. The phenotypes associated with all four of these subjects were highly correlated based 278 
upon analyses of HPO reported terms (HPO-sim P-value=0.006; see Methods and Supplementary 279 
Table 11)66,67, and were consistent with the multiple previous reports of subjects with dysregulation of 280 
FOXG1 (Supplementary Figure 11)62,68,63-65. At 6q14.3, four BCAs were localized in proximity to 281 
SYNCRIP, a highly constrained gene in which dnLoF had been reported in two subjects with 282 
neurodevelopmental disorders69. In one subject the BCA directly disrupted SYNCRIP, while another 283 
subject harbored a breakpoint distal to SYNCRIP that was part of a cryptic 6q14.3 deletion 284 
encompassing the full gene, though the impact of the other two BCAs was unclear due to their 285 
localization to an adjacent contact domain (Supplementary Fig. 12). Finally, a systematic screen 286 
identified four additional subjects in which a TAD disruption could represent a positional effect on 287 
known syndromic loci associated with a developmental disorder that closely matched the subject's 288 
phenotype (PITX2, SLC2A1, SOX9, SRCAP; Supplementary Fig. 13-15). In two of these regions, LCLs 289 
were available from the corresponding subjects and expression of the proposed driver gene was 290 
significantly reduced when compared to a 16-sample control panel (SLC2A1 and SRCAP, 291 
Supplementary Fig. 13 and 14). 292 
 293 
Collectively, 7.3% of subjects harbored a BCA predicted to alter long-range regulatory interactions 294 
involving an established syndromic locus with comparable phenotype, recurrently involving MEF2C, 295 
SATB2, and FOXG1 while an additional four subjects harbored a BCA that could represent long-range 296 
positional effects (two confirmed by expression studies), though our sample sizes precluded detection of 297 
a significant accumulation of breakpoints in these latter four regions. These data suggest that alterations 298 
to TAD structures likely represent a significant component of the deleterious impact of mutations 299 
associated with genomic rearrangements.   300 
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DISCUSSION 301 
This characterization of BCAs at nucleotide resolution offers new insights into their mechanisms of 302 
formation, the properties connected to their rearrangement in the nucleus, and a substantial yield of 303 
potentially novel genes associated with human development. These results also emphasize that neither 304 
the mere presence of a BCA in a subject with developmental defects nor the number of genes it disrupts 305 
(if any) provide sufficient prognostic power, but rather that the properties of the specific genes and 306 
regions that are altered are the most informative in predicting resultant phenotypes. These data build 307 
upon recent studies on genome topology and provide further evidence that alterations to chromosome 308 
structure can lead to alternative, yet potentially predictable, pathogenic mechanisms by changing the 309 
long-range regulatory architecture of physical interactions and chromatin looping in the nucleus66,60,61. 310 
The yield of clinically meaningful results in this study, which ranged from 26.6% to 46.4% of the 311 
subjects evaluated, was substantial. Nonetheless, the relative enrichment from cytogenetic studies of 312 
BCAs in subjects with developmental abnormalities compared to controls suggests that there are yet 313 
additional alternative pathogenic mechanisms associated with de novo chromosomal rearrangements that 314 
remain to be discovered4,5. 315 
 316 
These data provide an initial vantage of the potential utility of emerging datasets that characterize the 317 
nuclear organization of the chromosomes. They propose novel pathogenic mechanisms by which BCAs 318 
may operate, which appear to be a consequence of the disruption of long-range interactions between 319 
regulatory elements and their target gene66,60,61. Structural variants can indeed easily scramble DNA 320 
topology and contact domains with potentially dramatic regulatory consequences. TADs cover a 321 
substantial fraction of the genome; therefore, the vast majority of structural variation will perturb one of 322 
those domains and cannot constitute a predictive criterion for pathogenicity per se. These data propose 323 
that the recurrent disruption of a TAD encompassing a high confidence locus beyond what is expected 324 
by chance, concomitant with strong phenotypic overlap between the carrier of the variant and 325 
haploinsufficiency of the locus in independent subjects, may be a first step towards highlighting putative 326 
positional effects, though definitive conclusions will still require functional validation. Expression 327 
studies in peripheral blood cells of individual subjects are a plausible, yet suboptimal, method for 328 
confirming positional effects. There is clearly a need for sensitive and specific tools to predict such 329 
positional effects caused by long-range regulatory perturbations, and to annotate further the morbid 330 
genome with more complete knowledge of these functional interactions. The fraction of BCAs in this 331 
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study that may be associated with this pathogenic mechanism is therefore just an entrée into their likely 332 
significance as a component of the unexplained genetic contribution to human birth defects. 333 
 334 
In terms of evaluating diagnostic strategies, this study further highlights limitations of current diagnostic 335 
tools such as karyotyping or CMA in interpreting and detecting BCAs11,13-16. While the capability to 336 
visualize the chromosomes and detect de novo BCAs by traditional karyotyping represented a critical 337 
leap in genetic diagnostics, as exemplified by the seminal population cytogenetic studies performed by 338 
our late co-author, Dorothy Warburton10, the detection of gross chromosomal abnormalities provides 339 
limited prognostic capability as to the clinical manifestation that may present in a given case. Our data 340 
demonstrate that karyotyping significantly underestimates complex rearrangements and is almost always 341 
revised by at least a sub-band. Karyotyping is also insensitive to genomic imbalances observed in the 342 
human germline that cannot be directly visualized (~5-10 Mb). By comparison, CMA is generally 343 
recommended as a first-tier diagnostic screen given its sensitivity to detect submicroscopic CNVs, yet it 344 
is blind to copy-neutral events such as those described herein. This study provides critical new insights 345 
into the fraction of BCAs that can be ascertained by CMA analyses. Compared to cytogenetic estimates 346 
suggesting that up to 40% of BCAs resolved as unbalanced rearrangements and could therefore be 347 
ascertained using CMA25, whole-genome sequencing in this cohort suggests that, even at the resolution 348 
of 100 kb, only about 12% of BCAs involved a genomic imbalance. If we consider only the 102 subjects 349 
for whom no CMA was previously performed, this proportion increases to 18.8% at 100 kb resolution 350 
and 17.6% at 500 kb resolution, suggesting that 81.8-82.4% of BCAs in this study would be inaccessible 351 
to the resolution of most CMA platforms routinely used in clinical diagnostics. Notably, there is still 352 
benefit to an initial CMA screen, as is illustrated by the significantly lower yield of pathogenic BCAs 353 
among subjects who had been pre-screened by CMA (19-37%) compared to those who had not (41-354 
64%; Fig. 2e), indicating that a fraction of pathogenic variation in these genomes was captured by the 355 
CMA prescreen either in relation to or independent of the BCA.  356 
 357 
These data strongly argue for the implementation of technologies capable of detecting both balanced and 358 
unbalanced genomic rearrangements. This could be achieved by using a conventional cytogenetic test 359 
followed by a reflex WGS analysis when an abnormality is detected, which we have previously 360 
demonstrated can provide access to all classes of structural variation in the human genome while being 361 
accomplished in a relatively rapid timeframe12,70. Despite its great promise, it is important to recognize 362 
the limitations of massively parallel sequencing in routine cytogenetic practice. This study used large-363 
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insert jumping libraries to maximize physical coverage and minimize cost per base of genome covered. 364 
Yet these analyses failed to reveal breakpoints in 9% of BCAs tested, and our simulations indicate that 365 
at large sample sizes, we would anticipate ~7-8% of breakpoints to be undetectable by short-read 366 
sequencing. At present, this result gives credence to maintaining the parallel visualization of structural 367 
changes in the genome using traditional cytogenetic approaches such as karyotyping for regions that are 368 
recalcitrant to massively parallel sequencing. As sequencing technologies and analytical capabilities 369 
improve, this component of the variant spectrum will become more tractable to genomic approaches, 370 
and the future implementation of long-read sequencing may revolutionize the capacity to survey 371 
currently inaccessible segments of the human genome71,72. 372 
 373 
In conclusion, these data indicate that de novo BCAs represent a highly penetrant mutational class in 374 
human disease, and that their delineation can provide prognostic insights not available at current 375 
cytogenetic resolution. Although encouraging, this yield does not explain all of the developmental 376 
anomalies in this cohort and suggests that additional pathogenic mechanisms await discovery. A 377 
meaningful fraction may be attributable to novel genes or regulatory alterations, but additional 378 
pathogenic mechanisms remain to be explored such as recessive modes of inheritance, gene fusions, 379 
disruption of imprinted regions, enhancer adoption73,66, and more complex oligogenic models. 380 
Evaluation of extremely large cohorts will be required to resolve further such mechanisms, and 381 
characterization of BCAs in control populations would benefit annotation of the morbid human genome 382 
and interpretation of the biological and clinical consequences of its structural rearrangement. 383 
384 
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METHODS 385 
Methods and any associated references are available in the online version of the paper. 386 
 387 
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ONLINE METHODS 423 
Subject Ascertainment 424 
Subjects were enrolled through cytogenetic reference centers including DGAP (the Developmental 425 
Genome Anatomy Project) of Brigham and Women's Hospital and Massachusetts General Hospital, 426 
Boston, MA; Mayo Clinic, Rochester, MN; University Medical Center, Utrecht, NL; Radboud 427 
University, Nijmegen Medical Center, Nijmegen, NL. Enrollment was based on the presence of a 428 
developmental anomaly and concomitant BCA (de novo or that segregated with the abnormal 429 
phenotype) detected by karyotyping, and exclusion of clinically significant genomic copy number 430 
imbalances using chromosomal microarray analyses (SNP array or array-CGH) when possible (171/273 431 
tested subjects; Supplementary Fig. 1). In the majority of cases the BCA was confirmed to have arisen 432 
de novo by karyotyping (184/273) or segregated with a developmental phenotype in the family (14/273). 433 
In a subset of subjects: (1) the BCA was inherited but the phenotype of the transmitting parent was not 434 
available (3/273); (2) one parent was available and did not harbor the BCA (4/273); or (3) neither 435 
parents were available for testing (68/273). An informed consent was obtained from all subjects or their 436 
legal representative for participation in the study. All studies were approved by respective Institutional 437 
Review Boards. 438 
 439 
Whole-genome sequencing using large-insert jumping libraries 440 
Samples were prepared using multiple sequencing methods over several years (Supplementary Table 441 
1). Most samples were sequenced using whole-genome large-insert jumping library preparation 442 
protocols for subsequent Illumina sequencing: 149 using our 2x25-bp EcoP15l protocol11,74, 59 using a 443 
variant of our jumping library protocol in which we randomly shear circularized DNA, which enables 444 
longer reads (paired-end 50 bp, see Supplementary Methods) and 19 using standard Illumina mate-pair 445 
protocols. All large-insert sequencing methods allowed generation of paired-end reads with median 446 
insert size of 2.5-3.5 kb as opposed to 300 bp using conventional methods. A subset of samples were 447 
prepared with standard short-insert paired-end protocols (n=12) or targeted sequencing of the 448 
breakpoints based on previous positional cloning to narrow the breakpoint regions (n=34), as previously 449 
described75,11,7. Of note, 87 BCAs had been initially reported in the literature, though many had not been 450 
mapped to sequence resolution (Supplementary Table 1). 451 
 452 
Digitalization and homogenization of reported phenotypes 453 
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Clinical description was converted for all 273 subjects into standardized terms using Human Phenotype 454 
Ontology (HPO; Supplementary Table 2)19. Such digitalization allowed systematic comparison of 455 
phenotypes between subjects carrying BCAs that disrupted the same gene, as well as between subjects 456 
with a disrupted gene to previously described subjects using Phenomizer76. HPO-sim was used to 457 
compute phenotypic similarity scores between subjects sharing the disruption of the same gene or locus 458 
compared to random expectations (Supplementary Table 11)67. 459 
 460 
BCA discovery pipeline and breakpoint inference 461 
All computational analyses have been previously described70,77. In brief, reads were reverse-462 
complemented and aligned using BWA78. Anomalous read-pairs in terms of insert size, mate mapping, 463 
or mate orientation were extracted using Sambamba and clustered using ReadPairCluster, our single-464 
linkage clustering algorithm11,79. Anomalous read-pair clusters meeting our established thresholds of 465 
structural variation were subsequently classified based on their read-pair orientation signature into the 466 
following categories: deletions, insertions, inversions, and translocations77. When no clusters were found 467 
that matched the proposed karyotype, BAM files were agnostically analyzed and manually inspected for 468 
anomalous pairs or split reads. Breakpoints were successfully identified in 248 of 273 cases, leading to 469 
an overall breakpoint fine-mapping yield of 91%. All subsequent counts and yields were computed 470 
relative to mapped cases (n=248). For the remaining 25 unmapped cases, no breakpoints were identified 471 
in proximity to the karyotype interpretation following extensive analyses and visual inspection. For the 472 
majority of these latter unresolved cases, one or more breakpoints were interpreted by the karyotype to 473 
localize near centromeres heterochromatic regions, or within segmental duplications, which are 474 
recognized to be blind spots for short-read alignments. All large genomic imbalances predicted to be 475 
connected to BCA breakpoints following rearrangement reconstruction were confirmed to have aberrant 476 
depth of coverage using a custom R-script (CNView: https://github.com/RCollins13/CNView). 477 
When additional DNA was available, precise breakpoint junctions were delineated at base-pair 478 
resolution by Sanger sequencing and final breakpoints coordinates reported; else the reported 479 
coordinates reflect the minimal breakpoint estimates based on the resolution of the jumping libraries 480 
(Supplementary Table 3). A total of 82.7% (725/876) of the reported breakpoints could be tested by 481 
Sanger sequencing given DNA availability, among which 662 were confirmed yielding a minimum 482 
estimate of 91.3% (662/725) sensitivity for our mapping method. 483 
 484 
Molecular signature of BCA breakpoints 485 
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As previously described23, we processed all Sanger sequences from validated breakpoints with the BWA 486 
Smith-Waterman algorithm (modified parameters z 100 -t 3 -H -T 1) to retrieve precise breakpoint 487 
coordinates as well as infer the associated microhomology, micro-insertions or blunt end signature. This 488 
approach was sufficiently high-throughput to enable the direct comparison of BCA breakpoints with a 489 
large set of deletion breakpoints published by Abyzov et al.27, at the cost of not allowing concomitant 490 
microhomology and base insertions at breakpoints. 491 
 492 
Monte-Carlo randomization tests 493 
A Browser Extensible Data (BED) file containing GRCh37/hg19 genomic coordinates of all 876 494 
breakpoints detected by WGS was used as the input. One simulation consisted of generating random 495 
coordinates based on each pair of input coordinates, conserving the size of the feature as well as the 496 
intra-chromosomal distance when several breakpoints were localized to the same chromosome in a 497 
single individual. N-masked regions were excluded from simulations for consistency as they were 498 
excluded from the initial alignment mapping. Simulations were repeated 100,000 times. The number of 499 
unique intersections between the shuffled file and a BED-file containing features of interest (gene-sets, 500 
regulatory elements, etc.) was retrieved for each simulation, and the final sets of simulations delineated 501 
the expected distribution on intersections under the null hypothesis. The observed value of intersected 502 
features in this study was compared to this expected distribution. Empirical Monte-Carlo P-values were 503 
indicated, and were calculated as follows: P-value = (r + 1)/(n + 1), where r is the number of 504 
observations within the set of simulations that are at least as extreme as the one observed, and n is the 505 
total number of simulations80. References for all functional element datasets and genesets that were used 506 
to test for enrichment at breakpoints in the cohort are detailed in Supplementary Table 12. 507 
 508 
BCA outcome interpretation 509 
To build reference lists of genes associated with dominant developmental disorders we amalgamated 510 
data from multiple large-scale exome sequencing, genome sequencing, or CNV studies investigating 511 
developmental (e.g. DDD consortium) and neurodevelopmental disorders (mostly intellectual disability, 512 
autism, and epilepsy cohorts; see Supplementary Methods and Supplementary Table 6 for detailed 513 
references). We then built our interpretation using standard categories comparable to those established 514 
by ClinVar and the Deciphering Developmental Disorders consortium (DDD)44, as detailed below and in 515 
Supplementary Table 7. 516 
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Pathogenic: Confirmed Loci associated with developmental disorders. Any gene with three or more 517 
de novo LoF mutations (frameshift, nonsense or splice mutation, CNV, or BCA) reported from 518 
independent cases in those amalgamated studies or in OMIM was considered as high confidence for a 519 
particular phenotype, and any BCA impacting one of those loci was therefore considered to be 520 
Pathogenic (Supplementary Table 9).  521 
Likely Pathogenic: Novel candidate genes or mechanisms. To evaluate the impact of the remaining 522 
BCAs and the genes they likely impacted, we relied on convergent genomic evidence from other large-523 
scale datasets to prioritize which gene would most likely contribute to the subject’s phenotype. Multiple 524 
BCAs were considered to be Likely Pathogenic, based on various evidences (Supplementary Table 525 
10):  526 
(1) Disruption of a likely risk factor: Disruption of one copy of a gene in which one or two dnLoF 527 
mutations had been previously reported and which demonstrated significant constraint (top 10% of 528 
constrained genes)29,30 529 
(2) Novel mechanisms: Disruption of a gene established as associated with dominant developmental 530 
disorders yet with a distinct mutation type (e.g. activating or missense mutations while we reported LoF) 531 
(3) Disruption of long-range interactions: BCA breakpoints located in the vicinity of a gene associated 532 
with dominant developmental disorders in a subject with a consistent phenotype, and predicted to impact 533 
long-range regulatory interactions. 534 
VUS: All BCAs impacting genes not fitting in any of the above-mentioned categories were considered 535 
as VUS. 536 
 537 
Predicted disruption of contact domains by BCAs 538 
Topological associated domains (TADs) and predicted loops for lymphoblastoid cells were retrieved 539 
from Dixon et al. and Rao et al.59,18, and genes contained within a domain for which at least one of its 540 
insulating boundaries was disrupted by a BCA were assessed. Only genes that had been previously 541 
robustly associated with dominant developmental disorders (i.e., with dnLoF reported in three or more 542 
subjects) were considered for potential positional effects. A detailed comparison of the reported 543 
phenotypes in the corresponding subjects to phenotypes associated with disrupted genes in the literature 544 
was performed. For subjects identified with a BCA of plausible positional effect, the region was 545 
visualized using Juicebox18,81 (Supplementary Fig. 10-15). Heatmaps represent observed 546 
intrachromosomal interactions in GM12878 lymphoblastoid cells in a specific window; previously 547 
reported contact domains (regions of increased contact, not necessarily materializing as loops) and loops 548 
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(sites of increased focal contacts indicating the presence of a loop) were indicated59,18, as well as the 549 
RefSeq genes located in the region. 550 
 551 
Measuring gene expression from lymphoblasts 552 
In subjects for whom the BCA was suspected to result in positional effects and for whom LCLs derived 553 
from blood were available, gene expression was investigated by quantitative RT-PCR. LCLs were not 554 
tested for mycoplasma contamination. Total RNA was extracted from LCLs using TRIzol® (Invitrogen) 555 
followed by RNeasy Mini Kit (Qiagen) column purification. cDNA was synthetized from 750 ng of 556 
extracted RNA using SuperScript® II Reverse Transcriptase (ThermoFisher Scientific with oligo(dT), 557 
random hexamers, and RNase inhibitor. Quantitative RT-PCR was performed for mRNA expression of 558 
genes of interest in the following subjects (MEF2C: DGAP131, DGAP191, DGAP218, DGAP222; 559 
SATB2: DGAP237; SLC2A1: DGAP170; SRCAP: DGAP134) using custom designed primers (see 560 
Supplementary Methods). ACTB, GAPDH and POLR2A were each used as independent endogenous 561 
controls. Custom designed primers (0.75 µM final), cDNA (1:100 final) and nuclease-free water were 562 
added to the LightCycler® 480 SYBR Green I Master Mix (Roche) for a final 10 µL reaction volume. A 563 
LightCycler® 480 (Roche) was used for data acquisition. Values of each individual (subject or control) 564 
were obtained in three technical replicates. Results of technical replicates for each gene of interest were 565 
normalized against the average of the three endogenous controls (ACTB, GAPDH and POLR2A). 566 
Normalized expression levels were set in relation to eight age and sex-matched controls for the genes of 567 
interest SATB2, SLC2A1 and SRCAP, or 16 (eight males, eight females) age-matched controls for the 568 
gene of interest MEF2C, using the ΔΔCt method. Results are expressed as fold-change relative to the 569 
averaged control individuals. The significance of differential gene expression from a subject in 570 
comparison to controls was tested using a two-sided Wilcoxon Mann-Whitney test. All qRT-PCR results 571 
were independently replicated twice in the laboratory. 572 
573 
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TABLES  574 
Table 1. Overview of clinical phenotypes for all 273 subjects 575 
 576 
 Affected 
 subjects 
Frequency 
in cohort 
Gender   
Male 159 58.2% 
Female 114 41.8% 
Co-Segregation   
De novo 184 67.4% 
Unknown 75 27.5% 
Inherited, segregating 14 5.1% 
array-CGH analyses   
Normal 139 50.9% 
VUS 32 11.7% 
Not Performed 102 37.4% 
Abdomen defects 54 19.8% 
Cardiovascular defects 41 15.0% 
Eye defects 54 19.8% 
Hearing defects 52 19/0% 
Genitourinary defects 50 18% 
Growth defects 64 23% 
Head/Neck/Craniofacial 
defects 
140 51% 
Integument defects 50 18.3% 
Limb defects 57 20.9% 
Musculature defects 71 26.0% 
Neurological defects 219 80.2% 
Behavior disorders 51 18.7% 
Developmental delay 159 58.2% 
Epilepsy 51 18.7% 
Hypotonia 41 15.0% 
ASD/autistic features 31 11.4% 
High functioning ASD 4 1.5% 
Respiratory defects 30 11.0% 
Skeletal defects 116 42.4% 
 577 
Clinical description was converted for all 273 subjects into standardized terms using Human Phenotype 578 
Ontology (HPO)19, which allowed systematic association with broad phenotypic categories for each 579 
enrolled subject. 580 
  581 
582 
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Table 2. Genes and loci disrupted by BCAs and likely associated with developmental disorders 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
 609 
 610 
 611 
Details on BCA interpretation are provided in Methods and Supplementary Table 7. Genes that have 612 
been associated to dominant developmental disorders and encompassed by genomic imbalances at 613 
breakpoints are indicated in brackets; lower-scripts indicate when a gene was disrupted by a BCA in 614 
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multiple subjects; upper-scripts report subjects with a BCA disrupting multiple genes/loci that may each 615 
contribute to their developmental phenotype	 and to distinct clinical features; a: Subject DGAP133; b: 616 
Subject DGAP317, c: subject DGAP002, d: subject DGAP316, e: subject NIJ2, f: subject DGAP168, g: 617 
subject DGAP172, h: DGPA196; i: DGAP246; j: DGAP237. 618 
619 
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FIGURES 620 
Figure 1. Characterization of BCAs detected by karyotyping at nucleotide resolution 621 
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a. Circos plot of all BCA breakpoints identified in the cohort by whole-genome sequencing and their 667 
distribution across all chromosomes82. One color is used per BCA to represent all rearrangement 668 
breakpoints in each individual subject. The scatter plot on the outside ring denotes breakpoint density 669 
per 1-Mb bin across the genome, with a blue arrow displaying the largest clustering of breakpoints at the 670 
5q14.3 cytoband; b. Scatter plot summarizing the overall genomic imbalance associated with all fully 671 
reconstructed BCAs at varying size thresholds. Curves represent the fraction of cases with final genomic 672 
imbalances greater than the corresponding size provided (see details in Supplementary Table 4). Solid 673 
lines denote the final genomic imbalances for all BCAs, and are further delineated by deletions (red) or 674 
duplications (blue) emphasizing that cryptic imbalances connected to breakpoints are predominantly 675 
copy-losses. The final genomic imbalances among fully mapped BCAs is also split between cases that 676 
have been pre-screened by chromosomal microarray (CMA; dashed line) versus cases without CMA 677 
data (dotted line); c. Sequence signatures of BCA breakpoints. Histogram representing nucleotide 678 
signatures at the junction of 662 Sanger-validated breakpoints: inserted nucleotides (blue), blunt ends 679 
(grey), microhomology (orange), or longer stretches of homology (red). 680 
681 
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Figure 2. De novo BCAs associated with congenital anomalies disrupt functionally relevant loci  682 
 683 
 684 
685 
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a. Genes localized to BCA breakpoints in subjects with congenital anomalies were significantly enriched 686 
for constrained genes (1: Petrovski et al.29 [P=0.027], and 2: Samocha et al.30 [P=0.0009]), 687 
embryonically-expressed genes (P=0.001), genes previously associated with autosomal dominant 688 
disorders (P=0.002), developmental disorders (P=0.00002), FMRP-target genes (1: Ascano et al.34, and 689 
[P=0.036], and 2: Darnell et al.33 [P=0.031]), and genes involved in chromatin remodeling (P=0.007). 690 
Each boxplot represents the expected distribution (median, first and third quartiles) based on total 691 
intersections between 100,000 sets of simulated breakpoints and a particular gene-set; red diamonds 692 
indicate the observed intersection values against the expected distribution. Empirical Monte-Carlo P-693 
values are indicated. P-values thresholds were denoted by: * = P≤0.05, ** = P≤0.01, *** = P≤0.001, 694 
**** = P≤0.0001; b. Venn diagram showing the detailed overlap of disrupted genes that had been 695 
previously associated with three neurodevelopmental phenotypes (intellectual disability, ASD, and 696 
epilepsy) in amalgamated exome and CNV studies. In black: high-confidence genes (3 or more de novo 697 
LoF mutations reported), in grey: low-confidence genes (two de novo LoF mutations). c-e) Pie charts 698 
illustrating diagnostic yields associated with the overall cohort and multiple subgroups of BCAs. 699 
Clinical interpretation was restricted to Pathogenic, Likely Pathogenic, or Variant of Unknown 700 
Significance (VUS), as described in the text. c. Diagnostic yield associated with 248 mapped BCAs from 701 
subjects with congenital or developmental anomalies; d. The overall diagnostic yield was significantly 702 
higher among BCAs that were confirmed to be de novo or segregated with the developmental phenotype 703 
(n=198, 186 mapped) compared to the yield from BCAs of unknown segregation status (n=75, 62 704 
mapped); e. The overall diagnostic yield associated with BCAs in which large pathogenic CNVs had 705 
been excluded by a CMA pre-screen (n=171, 160 mapped) was lower compared to the yield from BCAs 706 
that had not been previously screened by CMA (n=102, 88 mapped). 707 
 708 
709 
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Figure 3. Recurrent disruption of long-range regulatory interactions at the 5q14.3 locus 710 
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a. Manhattan plot showing the distribution of all BCA breakpoints in the cohort across each 1-Mb bin of 757 
the human genome. P-values were computed by comparing observed to expected cluster sizes after 758 
100,000 Monte Carlo randomizations, and corrected for the total number of windows interrogated. 759 
Corrected P-values associated with each cluster of breakpoints coming from independent BCAs are 760 
indicated. One cluster containing breakpoints from eight independent cases at 5q14.3 achieved genome-761 
wide significance demarcated by the red line (5q14.3 maximum P-value=7.7x10-9), while three other 762 
regions provided nominal evidence of an unusual cluster of breakpoints (P-value = 1x10-4), as 763 
highlighted. b. The 5q14.3 cluster of eight breakpoints overlaps with a region associated with the 764 
5q14.3-q15 microdeletion syndrome. Multiple pathogenic mechanisms appear to converge on a similar 765 
phenotypic consequence: multi-genic deletions that encompass MEF2C along with one or both TAD 766 
boundaries (n=68), MEF2C-intragenic deletions (n=12) or LoF mutations, deletions that do not 767 
encompass MEF2C but overlap one TAD boundary (n=13), and BCA breakpoints distal to or truncating 768 
MEF2C (breakpoints from the eight subjects reported in this study along with three previously reported 769 
subjects)52,57,15. Overlapping Hi-C data from LCLs suggest that the topology of the MEF2C-contact 770 
domain is lost in subjects carrying BCAs18, leading to altered expression of MEF2C. Multiple brain-771 
expressed enhancers are located in the region distal to MEF2C83, and three loops involving MEF2C have 772 
been observed in the region (yellow circles)18. Forward (green) and reverse (red) CTCF binding sites are 773 
shown, several of which overlap with MEF2C-associated loop and domain boundaries; c. A proposed 774 
model of the chromatin folding in the region defining a regulatory unit for MEF2C: a loop is formed 775 
anchored at bidirectional CTCF binding sites resulting in distal enhancers being bridged in close 776 
proximity to MEF2C promoter regulating MEF2C expression; d. Significantly decreased expression was 777 
observed in LCLs from subjects harboring BCAs that disrupt the MEF2C-associated TAD when 778 
compared to age-matched controls, suggesting regulatory changes via a positional effect that disrupts the 779 
MEF2C TAD based on real-time qRT-PCR compared to mean expression value from 16 age-matched 780 
controls using three technical replicates and normalized against the average of three endogenous 781 
controls (ACTB, GAPDH and POLR2A). Differential gene expression was tested using a Wilcoxon 782 
Mann-Whitney test (* P<0.05, ** P<0.01). 783 
784 
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Figure 4. Correlations between phenotypes and genes disrupted in subjects harboring pathogenic BCAs 785 
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Heatmap summarizing the correlation between disrupted genes at breakpoints of pathogenic BCAs and 820 
phenotypes reported in subjects from this study (Supplementary Table 2). For each gene, the 821 
phenotypes reported in the corresponding subject were digitalized using HPO terms and grouped 822 
together under broad HPO categories19. One tile represents the normalized count of HPO terms 823 
belonging to each broad category reported in the subject(s). The generated matrix of counts of HPO-824 
terms per category for each gene was normalized per gene, and genes were clustered together when 825 
sharing similarly affected organs. Five groups are delineated based on clustering: 1- genes associated 826 
with severe nervous system and craniofacial abnormalities (dark blue); 2- genes connected to severe 827 
neurological phenotypes (red); 3- genes associated with craniofacial abnormalities and moderate 828 
neurological symptoms (black); 4- genes associated with skeletal and limb abnormalities, and with 829 
milder neurological involvement (green); 5- genes without neurological involvement (light blue). 830 
 831 
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